NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
NAYA Biosciences (NASDAQ: NAYA) has expressed support for a recent U.S. presidential executive order aimed at improving access to fertility treatments. The order directs the Domestic Policy Council to develop policy recommendations within 90 days to protect IVF access and reduce out-of-pocket expenses for families dealing with infertility.
As a provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (IVC) fertility treatments, NAYA believes this initiative could positively impact its operations. The company highlighted that its FDA-cleared INVOcell device and IVC treatment process are "uniquely positioned to offer an efficient, effective, and more affordable treatment solution" aligned with the administration's cost-reduction goals.
NAYA operates fertility centers in Wisconsin, Alabama, and Georgia. CEO Steve Shum emphasized that "no one should have to choose between financial stability and starting a family" and committed to supporting efforts making fertility treatments more accessible and affordable.
NAYA Biosciences (NASDAQ: NAYA) ha espresso supporto per un recente ordine esecutivo presidenziale degli Stati Uniti volto a migliorare l'accesso ai trattamenti per la fertilità. L'ordine incarica il Consiglio della Politica Nazionale di sviluppare raccomandazioni politiche entro 90 giorni per proteggere l'accesso alla FIV e ridurre le spese dirette per le famiglie che affrontano problemi di infertilità.
In quanto fornitore di fertilizzazione in vitro (FIV) e coltura intravaginale in vivo (IVC), NAYA crede che questa iniziativa potrebbe avere un impatto positivo sulle proprie operazioni. L'azienda ha sottolineato che il suo dispositivo INVOcell approvato dalla FDA e il processo di trattamento IVC sono "posizionati in modo unico per offrire una soluzione di trattamento efficiente, efficace e più accessibile" in linea con gli obiettivi di riduzione dei costi dell'amministrazione.
NAYA gestisce centri di fertilità in Wisconsin, Alabama e Georgia. Il CEO Steve Shum ha enfatizzato che "nessuno dovrebbe dover scegliere tra stabilità finanziaria e la possibilità di formare una famiglia" e si è impegnato a sostenere gli sforzi per rendere i trattamenti per la fertilità più accessibili e convenienti.
NAYA Biosciences (NASDAQ: NAYA) ha expresado su apoyo a un reciente decreto ejecutivo presidencial de EE. UU. destinado a mejorar el acceso a los tratamientos de fertilidad. El decreto instruye al Consejo de Política Doméstica a desarrollar recomendaciones políticas en un plazo de 90 días para proteger el acceso a la FIV y reducir los gastos de bolsillo para las familias que enfrentan problemas de infertilidad.
Como proveedor de fertilización in vitro (FIV) y cultivo intravaginal in vivo (IVC), NAYA cree que esta iniciativa podría tener un impacto positivo en sus operaciones. La compañía destacó que su dispositivo INVOcell aprobado por la FDA y el proceso de tratamiento IVC están "posicionados de manera única para ofrecer una solución de tratamiento eficiente, efectiva y más asequible" alineada con los objetivos de reducción de costos de la administración.
NAYA opera centros de fertilidad en Wisconsin, Alabama y Georgia. El CEO Steve Shum enfatizó que "nadie debería tener que elegir entre la estabilidad financiera y formar una familia" y se comprometió a apoyar los esfuerzos para hacer que los tratamientos de fertilidad sean más accesibles y asequibles.
NAYA 바이오사이언스 (NASDAQ: NAYA)는 최근 미국 대통령의 행정명령을 지원한다고 밝혔습니다. 이 명령은 불임 문제를 겪고 있는 가족들이 IVF 접근을 보호하고 본인 부담 비용을 줄이기 위한 정책 권고안을 90일 이내에 개발하도록 국내 정책 위원회에 지시합니다.
체외 수정 (IVF) 및 체내 질내 배양 (IVC)의 제공자로서 NAYA는 이 이니셔티브가 자사의 운영에 긍정적인 영향을 미칠 수 있다고 믿고 있습니다. 회사는 FDA 승인을 받은 INVOcell 장치와 IVC 치료 과정이 행정부의 비용 절감 목표에 부합하는 "효율적이고 효과적이며 더 저렴한 치료 솔루션을 제공할 수 있는 독특한 위치에 있다"고 강조했습니다.
NAYA는 위스콘신, 앨라배마 및 조지아에서 Fertility Center를 운영하고 있습니다. CEO 스티브 섬은 "누구도 재정적 안정성과 가족을 시작하는 것 중에서 선택해야 하지 않는다"고 강조하며, 불임 치료를 더 접근 가능하고 저렴하게 만들기 위한 노력에 지지를 약속했습니다.
NAYA Biosciences (NASDAQ: NAYA) a exprimé son soutien à un récent décret exécutif présidentiel américain visant à améliorer l'accès aux traitements de fertilité. Le décret charge le Conseil de la politique intérieure de développer des recommandations politiques dans un délai de 90 jours pour protéger l'accès à la FIV et réduire les frais à la charge des familles confrontées à l'infertilité.
En tant que fournisseur de fécondation in vitro (FIV) et de culture intravaginale in vivo (IVC), NAYA estime que cette initiative pourrait avoir un impact positif sur ses opérations. La société a souligné que son appareil INVOcell approuvé par la FDA et le processus de traitement IVC sont "uniquement positionnés pour offrir une solution de traitement efficace, efficiente et plus abordable" alignée avec les objectifs de réduction des coûts de l'administration.
NAYA exploite des centres de fertilité dans le Wisconsin, l'Alabama et la Géorgie. Le PDG Steve Shum a souligné que "personne ne devrait avoir à choisir entre la stabilité financière et le fait de fonder une famille" et s'est engagé à soutenir les efforts visant à rendre les traitements de fertilité plus accessibles et abordables.
NAYA Biosciences (NASDAQ: NAYA) hat seine Unterstützung für eine kürzliche US-Präsidentielle Executive Order zum Ausdruck gebracht, die darauf abzielt, den Zugang zu Fruchtbarkeitsbehandlungen zu verbessern. Die Order weist den Nationalen Politikrat an, innerhalb von 90 Tagen politische Empfehlungen zu entwickeln, um den Zugang zur IVF zu schützen und die Eigenkosten für Familien, die mit Unfruchtbarkeit zu kämpfen haben, zu senken.
Als Anbieter von In-vitro-Fertilisation (IVF) und In-vivo-Intravaginalkultur (IVC) Fruchtbarkeitsbehandlungen glaubt NAYA, dass diese Initiative positive Auswirkungen auf ihre Geschäfte haben könnte. Das Unternehmen hob hervor, dass sein von der FDA genehmigtes INVOcell Gerät und der IVC-Behandlungsprozess "einzigartig positioniert sind, um eine effiziente, effektive und kostengünstigere Behandlungslösung anzubieten", die mit den Kostensenkungszielen der Verwaltung übereinstimmt.
NAYA betreibt Fruchtbarkeitszentren in Wisconsin, Alabama und Georgia. CEO Steve Shum betonte, dass "niemand zwischen finanzieller Stabilität und dem Gründung einer Familie wählen sollte" und sich verpflichtete, die Bemühungen zu unterstützen, Fruchtbarkeitsbehandlungen zugänglicher und erschwinglicher zu machen.
- Executive order could expand market for NAYA's fertility services
- NAYA's INVOcell technology positioned as cost-effective solution aligned with policy goals
- Company operates multiple fertility centers across three states (Wisconsin, Alabama, Georgia)
- FDA-cleared technology gives competitive advantage in potentially expanding market
- Benefits depend on actual implementation of policy recommendations
- Timeline for potential business impact uncertain with 90-day policy development period
- current insurance coverage (fewer than 20 states) remains a market challenge
Insights
The recent executive order targeting fertility treatment accessibility represents a potential catalyst for NAYA Biosciences' fertility business segment, though investors should carefully weigh both opportunities and limitations before drawing conclusions.
NAYA operates at the intersection of policy and fertility healthcare with two key assets: physical fertility clinics in three states (Wisconsin, Alabama, and Georgia) and their FDA-cleared INVOcell technology. The INVOcell device offers intravaginal culture (IVC) as an alternative to traditional IVF, potentially at lower cost - a critical factor given that a single conventional IVF cycle typically costs $12,000-$15,000 out-of-pocket.
The U.S. fertility services market, valued at approximately $8 billion annually, faces significant access barriers, with fewer than 20 states mandating any fertility coverage. This executive order could meaningfully expand the addressable market by directing the Domestic Policy Council to develop recommendations for reducing costs and expanding insurance coverage.
However, several factors temper the immediate investment impact:
- The 90-day recommendation timeline and subsequent implementation process mean any revenue impact is likely 12-24 months away at minimum
- NAYA's micro-cap status ($1.7M market cap) and low share price suggest financial challenges that could limit its ability to capitalize on market expansion
- The company's self-description as a "portfolio company" in multiple therapeutic areas indicates fertility may represent only a portion of their business focus
- Increased insurance coverage could potentially benefit larger, more established competitors with greater scale and resources
The INVOcell technology represents NAYA's most distinctive asset in this space. If policy changes drive patients toward more cost-effective fertility solutions, NAYA could benefit disproportionately - but only if they can effectively scale operations and marketing. Their presence in states currently lacking fertility coverage mandates (Alabama, Georgia) could position them strategically if federal policy drives expanded coverage.
For investors, this development warrants monitoring the specific policy recommendations emerging from the Domestic Policy Council, NAYA's quarterly financial performance, and any strategic initiatives to capitalize on potential regulatory tailwinds. While promising, the executive order represents an early-stage policy development rather than an immediate financial catalyst.
NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell Technology
SARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, proudly supports the U.S. President’s recent executive order aimed at reducing the cost of IVF and expanding access to fertility services. The order directs the Domestic Policy Council to develop policy recommendations within 90 days to protect IVF access and significantly lower out-of-pocket expenses and health plan costs for families dealing with infertility.
For many individuals and couples struggling with infertility, the high cost of IVF often makes treatment financially out of reach. The lack of comprehensive insurance coverage for fertility services in most states further compounds this challenge, forcing many patients to take on significant debt or forego treatment altogether.
“Infertility is a challenging medical condition, and no one should have to choose between financial stability and starting a family,” said Steve Shum, CEO of NAYA Biosciences. “President Trump’s executive order is a critical step in the right direction, and we stand ready to support efforts that make fertility treatments more accessible and affordable for all. In addition to our existing fertility clinic operations, we also believe our FDA-cleared INVOcell device and the IVC treatment process is uniquely positioned to offer an efficient, effective, and more affordable treatment solution, which is aligned with the administration’s efforts to reduce costs.”
Currently, fewer than 20 states mandate some level of fertility coverage, leaving millions without insurance assistance. By addressing cost concerns, the administration’s action has the potential to bring hope to those who have faced heartbreaking obstacles on their journey to parenthood.
“As a trusted partner in fertility care with centers in Wisconsin, Alabama, and Georgia, NAYA remains committed to providing high-quality, patient-centered treatment and advocating for policies that support individuals and families seeking to conceive. We look forward to working alongside policymakers, medical professionals, and advocacy groups to ensure that every hopeful parent has the opportunity to experience the joy of building a family,” Shum concluded.
About NAYA Women’s Health
NAYA Women’s Health is currently focused within the fertility marketplace. Our commercial strategy includes operating fertility-focused clinics providing treatment to patients via INVO Centers, LLC, our wholly owned subsidiary. We currently have two operational INVO Centers in the United States along with a conventional IVF clinic.
Naya Women’s Health also includes the INVOcell medical device. The INVOcell is the first in vivo Intravaginal Culture (“IVC”) system granted FDA clearance in the United States. We believe this novel device and procedure provides a more natural, safe, effective and economical fertility treatment for patients. Unlike conventional infertility treatments such as IVF where the eggs and sperm develop into embryos in a laboratory incubator, the INVOcell utilizes the women’s vagina as an incubator to support a more natural fertilization and embryo development environment, and infertility treatment. We currently sell and distribute INVOcell into existing independently owned and operated fertility clinics as well as within our own INVO Center clinics.
About NAYA Biosciences
NAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Our proven hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics.
NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
NAYA Investor & Media Contact
Anna Baran-Djokovic
SVP, Investor Relations
+1-305-615-9162
anna@nayabiosciences.com
FAQ
How might the recent executive order on fertility treatments affect NAYA Biosciences (NAYA) stock?
What is NAYA Biosciences' INVOcell technology and how does it relate to the executive order on fertility treatments?
Where does NAYA Biosciences currently operate fertility centers as mentioned in the February 2025 announcement?
What specific timeline did the executive order set for developing fertility treatment policy recommendations according to NAYA's press release?
How many states currently mandate fertility coverage according to NAYA Biosciences' February 2025 press release?
